Pfizer, BioNTech Pause US COVID Vaccine Study Due to Recruitment Issues

• The FDA introduced stricter trial requirements in 2024, including large placebo-controlled trials for the 50-64 age group, and no COVID vaccines have been approved for that demographic since
• Pfizer stopped surveillance for COVID illness among study participants after April 3, with enrollment having closed on March 6 following review of epidemiological trends
• The decision reflects broader industry challenges with weak U.S. vaccine uptake and pushback from the current administration

Pfizer and BioNTech Halt U.S. COVID Vaccine Trial Due to Low Enrollment

Pfizer and BioNTech have stopped recruitment for a major U.S. clinical trial of their updated COVID-19 vaccine targeting healthy adults aged 50-64, citing insufficient enrollment rather than safety concerns. The companies closed enrollment on March 6 and will cease surveillance for COVID illness among participants after April 3, according to a March 30 letter to trial investigators.

Key Details:

• Target enrollment was approximately 25,000-30,000 participants, which was not achieved
• The halt stems from "slow enrollment and therefore the inability to generate relevant post-marketing data"
• Both companies have informed the FDA of their decision

Regulatory Context:

The trial faced headwinds from stricter FDA requirements implemented in 2024, which mandated large, placebo-controlled trials for the 50-64 age group to secure approval for that demographic. Since these requirements took effect, no COVID vaccines have been approved for this age bracket.

Market Challenges:

The study's failure reflects broader industry obstacles, including:

• Weak COVID vaccine uptake in the U.S.
• Pushback from the current U.S. administration
• Declining public interest in COVID vaccinations

Implications:

This development highlights the evolving COVID vaccine landscape, where reduced disease prevalence and vaccination fatigue make conducting large-scale trials increasingly difficult. The inability to complete trials for the 50-64 age group may limit vaccine recommendations and market access for this demographic, potentially impacting future revenue streams for both pharmaceutical companies. The halt underscores shifting dynamics in the post-pandemic vaccine market as companies navigate regulatory hurdles amid declining demand.